Related Experiment Video
Updated: May 12, 2026

Targeted Next-generation Sequencing and Bioinformatics Pipeline to Evaluate Genetic Determinants of Constitutional Disease
Published on: April 4, 2018
Toll-like receptor 1 N248S single-nucleotide polymorphism is associated with leprosy risk and regulates immune
Carolinne de Sales Marques1, Vânia N Brito-de-Souza, Luana Tatiana Albuquerque Guerreiro
1Laboratório de Hanseníase, Instituto Oswaldo Cruz, Av. Brasil 4365, Manguinhos Rio de Janeiro, RJ, Brazil.
Abstract:
Conflicting findings about the association between leprosy and TLR1 variants N248S and I602S have been reported. Here, we performed case-control and family based studies, followed by replication in 2 case-control populations from Brazil, involving 3162 individuals. Results indicated an association between TLR1 248S and leprosy in the case-control study (SS genotype odds ratio [OR], 1.81; P = .004) and the family based study (z = 2.02; P = .05). This association was consistently replicated in other populations (combined OR, 1.51; P < .001), corroborating the finding that 248S is a susceptibility factor for leprosy. Additionally, we demonstrated that peripheral blood mononuclear cells (PBMCs) carrying 248S produce a lower tumor necrosis factor/interleukin-10 ratio when stimulated with Mycobacterium leprae but not with lipopolysaccharide or PAM3cysK4. The same effect was observed after infection of PBMCs with the Moreau strain of bacillus Calmette-Guerin but not after infection with other strains. Finally, molecular dynamics simulations indicated that the Toll-like receptor 1 structure containing 248S amino acid is different from the structure containing 248N. Our results suggest that TLR1 248S is associated with an increased risk for leprosy, consistent with its hypoimmune regulatory function.
Related Concept Videos
Single Nucleotide Polymorphisms-SNPs
Non-LTR Retrotransposons
Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters
Inflammatory Bowel Disease III: Crohn's Disease
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
lncRNA - Long Non-coding RNAs
